NCT03906526 - A Study to Evaluate Immune Biomarker Modulation in Response to VTX-2337 in Combination With an Anti- PD-1 Inhibitor in Head and Neck Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

July 3, 2019

Primary Completion Date

January 24, 2022

Study Completion Date

January 24, 2022

Conditions

Carcinoma, Squamous Cell

Interventions

DRUG

VTX-2337

Motolimod

DRUG

Nivolumab

IV Nivolumab

Trial Locations (12)

Local Institution - 101, Pittsburgh

University of Pittsburgh Medical Center Hillman Cancer Center, Pittsburgh

The Ohio State University Comprehensive Cancer Center, Columbus

Local Institution - 102, St Louis

Washington University, St Louis

Local Institution - 112, Birmingham

University of Alabama at Birmingham, Birmingham

Boston University, Boston

Local Institution - 116, Boston

University of Cincinnati, Cincinnati

Local Institution - 103, Sioux Falls

Sanford Cancer Center, Sioux Falls